FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2114178889> ?p ?o ?g. }

• W2114178889 endingPage "2069" @default.
• W2114178889 startingPage "2069" @default.
• W2114178889 abstract "A prospective, nonrandomized, multicenter, open feasibility study of cisplatin and docetaxel as first-line chemotherapy in International Federation of Gynecology and Obstetrics (FIGO) stage IC-IV epithelial ovarian cancer was conducted. The primary end point was the incidence of severe fluid retention that necessitated treatment withdrawal.Cisplatin and docetaxel were administered every 3 weeks for six planned cycles, with a 5-day prophylactic dexamethasone regimen (8 mg two times per day). One hundred patients (median age, 53 years; range, 24 to 71 years) received a total of 512 cycles of chemotherapy in two cohorts: cohort 1, 49 patients, 258 cycles (cisplatin 75 mg/m(2) and docetaxel 75 mg/m(2)); cohort 2, 51 patients, 254 cycles (cisplatin 75 mg/m(2) and docetaxel 85 mg/m(2)).No patients were taken off study because of fluid retention. Sixty-six patients completed six cycles of protocol therapy; 16 stopped early because of toxicity (neurotoxicity in six patients, nephrotoxicity in three, neutropenia in two, and hypersensitivity, diarrhea and vomiting, skin rash, clinical deterioration, and patient's wishes in one patient each). Grade 3/4 neutropenia was observed in more than 75% of patients and seemed to be cumulative. Patients in cohort 2 had significantly more severe neutropenia and lethargy than those in cohort 1. In addition, there were five treatment-related deaths in cohort 2 (three neutropenia and two upper gastrointestinal hemorrhage). Neurotoxicity (mainly sensory, > grade 1) was observed in 23 patients. The overall clinical response rate was 69% (complete response, 38%; partial response, 31%); CA-125 response rate was 73%. Median progression-free survival for the group was 12 months.Cisplatin and docetaxel can be administered at doses of 75 mg/m(2) and 75 mg/m(2), respectively, every 3 weeks, and the utility of this regimen is not limited by fluid retention. However, 33 of 100 patients were unable to complete the planned six cycles, which may explain, in part, the poor overall progression-free survival. Increasing the docetaxel dose to 85 mg/m(2) adds unacceptable hematologic toxicity and potential risks to the patient." @default.
• W2114178889 created "2016-06-24" @default.
• W2114178889 creator A5012852394 @default.
• W2114178889 creator A5014804968 @default.
• W2114178889 creator A5015578699 @default.
• W2114178889 creator A5033048625 @default.
• W2114178889 creator A5044372455 @default.
• W2114178889 creator A5044650126 @default.
• W2114178889 creator A5047823836 @default.
• W2114178889 creator A5051980635 @default.
• W2114178889 creator A5057088317 @default.
• W2114178889 creator A5057285559 @default.
• W2114178889 creator A5059449082 @default.
• W2114178889 creator A5077856400 @default.
• W2114178889 creator A5090337382 @default.
• W2114178889 creator A5090450124 @default.
• W2114178889 date "1999-07-01" @default.
• W2114178889 modified "2023-09-26" @default.
• W2114178889 title "Docetaxel and Cisplatin in Combination as First-Line Chemotherapy for Advanced Epithelial Ovarian Cancer" @default.
• W2114178889 cites W1827644950 @default.
• W2114178889 cites W1845622004 @default.
• W2114178889 cites W1935237200 @default.
• W2114178889 cites W1955744924 @default.
• W2114178889 cites W1968497980 @default.
• W2114178889 cites W1968785826 @default.
• W2114178889 cites W1983719103 @default.
• W2114178889 cites W2022808735 @default.
• W2114178889 cites W2031471596 @default.
• W2114178889 cites W2036045878 @default.
• W2114178889 cites W2037490361 @default.
• W2114178889 cites W2043478531 @default.
• W2114178889 cites W2067299834 @default.
• W2114178889 cites W2073533584 @default.
• W2114178889 cites W2075960393 @default.
• W2114178889 cites W2081406767 @default.
• W2114178889 cites W2085995564 @default.
• W2114178889 cites W2134495718 @default.
• W2114178889 cites W2137332723 @default.
• W2114178889 cites W2141258764 @default.
• W2114178889 cites W2145555831 @default.
• W2114178889 cites W2167805334 @default.
• W2114178889 cites W2328421677 @default.
• W2114178889 cites W3140157931 @default.
• W2114178889 cites W2328775832 @default.
• W2114178889 doi "https://doi.org/10.1200/jco.1999.17.7.2069" @default.
• W2114178889 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10561260" @default.
• W2114178889 hasPublicationYear "1999" @default.
• W2114178889 type Work @default.
• W2114178889 sameAs 2114178889 @default.
• W2114178889 citedByCount "68" @default.
• W2114178889 countsByYear W21141788892012 @default.
• W2114178889 countsByYear W21141788892013 @default.
• W2114178889 countsByYear W21141788892014 @default.
• W2114178889 countsByYear W21141788892015 @default.
• W2114178889 countsByYear W21141788892016 @default.
• W2114178889 countsByYear W21141788892017 @default.
• W2114178889 countsByYear W21141788892018 @default.
• W2114178889 countsByYear W21141788892019 @default.
• W2114178889 countsByYear W21141788892021 @default.
• W2114178889 countsByYear W21141788892022 @default.
• W2114178889 crossrefType "journal-article" @default.
• W2114178889 hasAuthorship W2114178889A5012852394 @default.
• W2114178889 hasAuthorship W2114178889A5014804968 @default.
• W2114178889 hasAuthorship W2114178889A5015578699 @default.
• W2114178889 hasAuthorship W2114178889A5033048625 @default.
• W2114178889 hasAuthorship W2114178889A5044372455 @default.
• W2114178889 hasAuthorship W2114178889A5044650126 @default.
• W2114178889 hasAuthorship W2114178889A5047823836 @default.
• W2114178889 hasAuthorship W2114178889A5051980635 @default.
• W2114178889 hasAuthorship W2114178889A5057088317 @default.
• W2114178889 hasAuthorship W2114178889A5057285559 @default.
• W2114178889 hasAuthorship W2114178889A5059449082 @default.
• W2114178889 hasAuthorship W2114178889A5077856400 @default.
• W2114178889 hasAuthorship W2114178889A5090337382 @default.
• W2114178889 hasAuthorship W2114178889A5090450124 @default.
• W2114178889 hasConcept C126322002 @default.
• W2114178889 hasConcept C141071460 @default.
• W2114178889 hasConcept C2776694085 @default.
• W2114178889 hasConcept C2777063308 @default.
• W2114178889 hasConcept C2778850193 @default.
• W2114178889 hasConcept C2781190966 @default.
• W2114178889 hasConcept C2781413609 @default.
• W2114178889 hasConcept C71924100 @default.
• W2114178889 hasConcept C72563966 @default.
• W2114178889 hasConcept C90924648 @default.
• W2114178889 hasConceptScore W2114178889C126322002 @default.
• W2114178889 hasConceptScore W2114178889C141071460 @default.
• W2114178889 hasConceptScore W2114178889C2776694085 @default.
• W2114178889 hasConceptScore W2114178889C2777063308 @default.
• W2114178889 hasConceptScore W2114178889C2778850193 @default.
• W2114178889 hasConceptScore W2114178889C2781190966 @default.
• W2114178889 hasConceptScore W2114178889C2781413609 @default.
• W2114178889 hasConceptScore W2114178889C71924100 @default.
• W2114178889 hasConceptScore W2114178889C72563966 @default.
• W2114178889 hasConceptScore W2114178889C90924648 @default.
• W2114178889 hasIssue "7" @default.
• W2114178889 hasLocation W21141788891 @default.
• W2114178889 hasLocation W21141788892 @default.

• next